Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
stocks
Market overreacts to earnings miss from moated ASX retailer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,245.00 | 66.30 | -0.71% |
CAC 40 | 7,843.04 | 126.65 | -1.59% |
DAX 40 | 24,273.12 | 89.97 | -0.37% |
Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,829.91 | 490.77 | 1.94% |
NASDAQ | 21,449.29 | 47.24 | -0.22% |
Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
S&P 500 | 6,439.32 | 27.59 | -0.43% |
S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
SSE Composite Index | 3,883.56 | 57.80 | 1.51% |